TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 255 filers reported holding TG THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8 | -63.6% | 900 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $22 | +57.1% | 900 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $14 | +27.3% | 900 | 0.0% | 0.00% | – |
| Q4 2022 | $11 | -99.8% | 900 | 0.0% | 0.00% | – |
| Q3 2022 | $5,000 | +25.0% | 900 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -77.8% | 900 | -52.6% | 0.00% | -100.0% |
| Q1 2022 | $18,000 | -88.4% | 1,900 | -76.7% | 0.00% | -85.7% |
| Q4 2021 | $155,000 | -22.9% | 8,140 | +34.8% | 0.01% | -30.0% |
| Q3 2021 | $201,000 | +58.3% | 6,040 | +84.6% | 0.01% | +66.7% |
| Q2 2021 | $127,000 | +101.6% | 3,272 | +151.7% | 0.01% | +100.0% |
| Q1 2021 | $63,000 | +293.8% | 1,300 | +333.3% | 0.00% | +200.0% |
| Q4 2020 | $16,000 | +23.1% | 300 | -40.0% | 0.00% | 0.0% |
| Q3 2020 | $13,000 | -31.6% | 500 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $19,000 | +90.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $10,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,890,000 | $15,800,400 | 5.14% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,360,000 | 2.75% |
| Soleus Capital Management, L.P. | 2,884,382 | $24,113,434 | 2.22% |
| M28 Capital Management LP | 216,600 | $1,810,776 | 2.08% |
| Paradigm Biocapital Advisors LP | 3,619,015 | $30,254,965 | 2.05% |
| 683 Capital Management, LLC | 1,350,000 | $11,286,000 | 0.88% |
| Parkwood LLC | 165,414 | $6,081 | 0.66% |
| Spotlight Asset Group, Inc. | 79,000 | $660,440 | 0.60% |
| Pier Capital, LLC | 392,709 | $3,283,047 | 0.53% |
| Quantum Private Wealth, LLC | 91,081 | $761,438 | 0.36% |